GRANT NO:  DAMD17-94-J-4351

TITLE:  Isolation of a Receptor for WNT/Wingless Growth Factors

PRINCIPAL INVESTIGATOR(S):  Roel Nusse, Ph.D.

CONTRACTING ORGANIZATION:  Stanford University
Stanford, California  94305-4125

REPORT DATE:  September 1995

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
Isolation of a Receptor for WNT/Wingless Growth Factors

Roel Nusse, Ph.D.

Stanford University
Stanford, California 94305-4125

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

The work done in this grant aims at elucidating the function of the Wnt signaling molecules in cancer. Wnt proteins are secreted and play important growth controlling roles, in particular in the mammary gland. They can act as oncogenes in mouse mammary tumors. The work is specifically aimed at identifying a receptor for Wnt proteins. The isolation of a receptor is critical to our understanding of normal growth control of the mammary gland. Using genetic and biochemical approaches we wish to identify and to clone the receptor for a Wnt gene product in Drosophila, called wingless. The receptor will be characterized and using the receptor gene, we will subsequently clone mammalian Wnt receptors by homology.
The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to stay within the lines to meet optical scanning requirements.

**Block 1.** Agency Use Only (Leave blank).

**Block 2.** Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3.** Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4.** Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5.** Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

| C | Contract |
| G | Grant |
| PE | Program |
| PR | Project |
| TA | Task |
| MU | Work Unit |
| Element | Accession No. |

**Block 6.** Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7.** Performing Organization Name(s) and Address(es). Self-explanatory.

**Block 8.** Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9.** Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

**Block 10.** Sponsoring/Monitoring Agency Report Number. (If known)

**Block 11.** Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a.** Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORD, REL, ITAR).

| DOD | See DoDD 5230.24, “Distribution Statements on Technical Documents.” |
| DOE | See authorities. |
| NASA | See Handbook NHB 2200.2. |
| NTIS | Leave blank. |

**Block 12b.** Distribution Code.

| DOD | Leave blank. |
| DOE | Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports. |
| NASA | Leave blank. |
| NTIS | Leave blank. |

**Block 13.** Abstract. Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report.

**Block 14.** Subject Terms. Keywords or phrases identifying major subjects in the report.

**Block 15.** Number of Pages. Enter the total number of pages.

**Block 16.** Price Code. Enter appropriate price code (NTIS only).

**Blocks 17-19.** Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20.** Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRONT COVER</td>
<td>1</td>
</tr>
<tr>
<td>REPORT DOCUMENTATION PAGE</td>
<td>2</td>
</tr>
<tr>
<td>FOREWORD</td>
<td>3</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>4</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>5</td>
</tr>
<tr>
<td>BODY</td>
<td>6-9</td>
</tr>
<tr>
<td>CONCLUSIONS</td>
<td>10</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>11</td>
</tr>
</tbody>
</table>
(5) Introduction

This grant aims at elucidating the function of the Wnt signaling molecules in cancer, in particular the identification of a receptor for Wnt proteins. Wnt genes encode secreted proteins involved in cell-to-cell signaling (Nusse and Varmus, 1992; McMahon, 1992). Wnt genes play important growth controlling roles, in particular in the mammary gland, and act as oncogenes in mouse mammary tumors (Nusse and Varmus, 1982). Little is known about the mechanism of action of Wnt products. Problems inherent to the nature of Wnt proteins have precluded the isolation and characterization of Wnt receptors. The isolation of these receptors is critical to our understanding of normal growth control of the mammary gland.

Using genetic and biochemical approaches generated by our work on a Wnt gene in Drosophila called wingless (Rijsewijk et al., 1987), we wish to identify and to clone the receptor for wingless. We perform genetic screens to identify suppressors and enhancers of an adult wingless phenotype. These modifying genes will be cloned and their properties will be examined by sequencing and transfection. We will also take advantage of our recently developed assay for soluble extracellular wingless protein to identify wingless receptors. The receptor will be characterized and using the receptor gene, we will subsequently clone mammalian Wnt receptors by homology.
(6) Body

6.1 Biochemistry of *wingless* signaling; characterization and isolation of the *wingless* protein.

We have developed a very useful *in vitro* assay for *wingless* signaling in our laboratory, using a cell line (clone 8 or cl-8) derived from *Drosophila* imaginal discs. These cells normally do not express *wingless* but we initially transfected cl-8 cells with constructs containing *wingless* alleles including the temperature sensitive mutant *wg*II.114. To measure a response to *wingless*, we examined the expression of the *armadillo* protein, the most ubiquitous downstream genetic target of *wingless* during the development of the fly. We found an approximately 15-fold increase in *armadillo* protein levels at the permissive temperature (16°C) compared to non-permissive temperature (29°C) in cl-8 cells expressing *wg*II.114.

We tested whether *wingless* from sources outside the target cells can also influence *armadillo* protein levels. In these assays, we used non-transfected cl-8 cells as targets, and *wingless* overexpressing S2 cells as donors (Cumberledge and Krasnow, 1993). These S2 cells were generated by transfection of expression constructs containing various *wingless* alleles. In the transfected S2 cells, *wingless* antigen was observed at the cell surface, in the extracellular matrix (ECM) and in the supernatant. This protein in the medium is soluble to the extent that a 100,000 g centrifuge spin leaves the protein in the supernatant (Van Leeuwen et al., 1994).

Using co-cultured *wingless*-producing S2 cells, the ECM, and also the medium from these S2 cells, we found a large increase in *armadillo* levels in the cl-8 target cells. Serum free medium conditioned by *wingless* overexpressing S2 cells or control cells was centrifuged at 100,000g for 1 hr. and concentrated. A significant induction of *armadillo* was seen in the cl-8 cells that had been incubated with the medium. To demonstrate that the active component in the concentrated tissue culture medium from the *wingless*-producing S2 cells was indeed the *wingless* protein, we added a rabbit antiserum that was raised to a bacterial fusion protein containing
wingless protein to the medium. The antisera removed the armadillo-
inducing effect from the medium, whereas a control pre-immune serum
had no effect.

In conclusion, we have found active soluble wingless protein in the
medium. This protein has a rapid, concentration-dependent effect on the
levels of the armadillo proteins. This activity can be depleted by an
antibody to wingless, providing a quantitative and early effect of an
extracellular Wnt protein (Van Leeuwen et al., 1994).

This assay has also been used to analyze the properties of the wingless
protein itself. By making a series of mutant forms and analyzing the size
of wingless protein on glycerol gradients, we found the active wingless
protein in a higher molecular weight complex. This complex could either
be a multimer of wingless itself or contain other, yet uncharacterized
proteins. Interestingly however, wingless in this complex is not bound
through disulfide linkages to other proteins, as non-reducing gels show
a monomeric form of the wingless protein within this complex. Epitope
tagged variants of wingless have been generated to purify active
protein. Thus, epitopes consisting of 6 His residues (The His tag) and of
the HA tag have been inserted into the wingless protein. We have also
made variants in which a substrate site for a protein kinase has been
inserted into the wingless protein, aiming at labeling the protein to high
specific activity with radiolabelled phosphate.

These variants have been transfected into Drosophila Schneider S2 cells,
and are like the wild type protein, secreted from cells in an active form.
The wingless protein will be isolated by a combination of affinity, ion
exchange and other chromatography methods and tested throughout
these steps by the assay described before. Monoclonal antibodies against
epitopes built into wingless will be used to generate immunoaffinity
matrices. This His-tag protein can be purified by nickel-chelate
chromatography. The wingless protein will be eluted by various methods,
as mild as possible, for example by competition using the peptides used to
raise the monoclonals, but otherwise by changing the pH, salt or
detergent concentrations.
6.2 A genetic screen for suppressors of a wingless phenotype in *Drosophila*

A second route to the identification of components of wingless signal transduction in *Drosophila* is to take advantage of the genetic tools developed in this organism. By performing genetic screens for suppressors of a wingless-caused phenotype in the fly, one can uncover mutations in genes that are essential to generate this phenotype. Those genes could encode components of the wingless signaling pathway, including the receptor.

To create a viable, dominant adult wingless phenotype, we have made several P-element based constructs to obtain ectopic expression of wingless in larval imaginal discs, the progenitors of adult tissues. These include a construct in which wingless expression is driven by the *sevenless* promoter, pSEW-wingless, which is known to be active only in the eye imaginal disc. The transgenic flies that were obtained have a very specific phenotype in the eye: an almost complete absence of interommatidial bristles. Normally these bristles arise throughout most of the eye in a regular pattern. While there are approximately 600 bristles in the wild-type eye, the pSEW-wingless flies have 0-10 bristles. Other structures in the eye and elsewhere are apparently normal. This phenotype is 100% penetrant and easy to score with a dissecting microscope.

Transgenic flies carrying a sevenless-driven temperature sensitive allele of wingless (pSEW-wingless(ts)) display the loss-of-bristle phenotype in a temperature-dependent manner. When this temperature dependent transgene is combined with a loss of function mutation in *armadillo*, the phenotype becomes suppressed. At 17.9°C approximately 200-300 bristles per eye form. When the dose of *armadillo* gene is reduced by a factor of two (flies heterozygous for a *armadillo* mutation), the number of bristles significantly increases. Thus, a reduction of *armadillo* gene activity can suppress the pSEW-wingless(ts) phenotype, suggesting that other components of the wingless-signaling pathway can be identified with this assay (Noordermeer et al., 1994). Moreover, this phenotype is also generated by a wingless temperature sensitive allele, but in a temperature dependent manner. The phenotype is fully
penetrant, as no wild type eyes have been detected at permissive or intermediate temperatures.

This penetrant adult viable *wingless* phenotype has been used to perform a genome wide screen for dominant suppressors or enhancers of *wingless*. The principle behind this screen is to search for mutations that will give a phenotype when one allele has undergone a loss-of-function mutation. Normally, complete absence of one allele will not give a phenotype. But in a genetic background where the phenotype of one gene (in this case *wingless*) is dosage-sensitive, absence of one copy of an interacting gene may modify this phenotype. These screens is been done in the F1 generation, so provided the phenotype to be used is easily scored under a dissection microscope (as the pSEW-*wingless*(ts) bristle phenotype is), large \(10^5\) numbers of mutagenized chromosomes can be screened. Especially since the phenotype is semi-quantitative (i.e. the number of bristles on the eye can be approximated) this screen is very sensitive to dosage of gene products interacting with *wingless*.

An advantage of the screen is that not only suppressors but also enhancers of the pSEW-*wingless*(ts) phenotype can be scored. By performing the crosses at an intermediate temperature, where about 30% of the normal number of bristles are formed, modifications resulting in either fewer (enhancers) or more (suppressors) bristles were identified. Thus, if the *wingless* receptor acts negatively in the absence of ligand, and this negative effect is relieved by binding of *wingless*, the genetic screen may still uncover a mutation in its gene.

We have now isolated approximately 20 suppressors and enhancers of the *wingless* phenotype in the eye. These genes have been mapped and have been assembled into complementation groups, a prerequisite for molecular cloning. We have also performed clonal analysis of these genes, indicating that some of them also have a phenotype in the homozygous state. The mapping data will now be used to start cloning these modifying genes.
(7) Conclusions

Since the work started, approximately one year ago, we have made significant progress on both lines in the original grant application. We have started the purification of the wingless protein, and we have isolated a fairly large number of genes modifying wingless signaling in Drosophila.
(8) References


